Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

June 26, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

1
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

2
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

3
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

4
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

5
September 22, 2023October 1, 2023

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • Effect of glucocorticoid treatment in early Rheumatoid Arthritis

Subcutaneous immunotherapy as an effective treatment for allergy

Genetic pathway behind neurological disorder in Rett syndrome

Effect of glucocorticoid treatment in early Rheumatoid Arthritis
  • BiotechToday
  • World

Effect of glucocorticoid treatment in early Rheumatoid Arthritis

BioTech Today July 9, 2021July 8, 2021

Sayak Banerjee, Amity University Kolkata

Rheumatoid Arthritis and osteoporosis:

Rheumatoid Arthritis (RA) is a chronic systemic inflammatory disease that mostly occurs in synovial joints. Its symptoms are local bone loss depicted by juxta-articular osteoporosis, and systemic bone loss depicted by generalized osteoporosis. Among these two symptoms, generalized osteoporosis is more common in patients with RA than in the general population, and this is often brought upon the risk of increased chances of fracture. The physiopathology of systemic inflammation of osteoporosis in RA and its treatment involving glucocorticoid (GC) are two chief determinants of bone loss. There are several regulators taking part in the pathogenesis of bone changes in RA, and these are modulated by GC. GC-induced bone loss is associated with the hindrance towards bone formation which in turn leads to the increase of bone adhesion related to the dysregulation of the osteoprotegerin (OPG) system.

Data analysis of Glucocorticoid treatment and bone quality:

There are only a few data available that observe changes in the bone during RA since a large number of patients with RA develop osteoporosis while the disease is in progression. The researchers from the Rheumatology Clinic of the University of Foggia, have mentioned their findings in their paper. They used Dual X-Ray absorptiometry (DXA) for the measurement of bone mineral density (BMD), although it is not sufficient to evaluate the parameters required to define bone strength. The trabecular bone score (TBS) is the structural index acquired from the DXA image analysis which enables the indirect assessment of bone microarchitecture implying bone quality. It has been seen that TBS provides further details concerning the changes in bone quality associated with GC treatment. It might be an essential tool for the evaluation of bone microarchitecture irrespective of BMD. A higher value of TBS corresponds to a better bone microarchitecture, whereas lower TBS is associated with poorer bone microarchitecture despite their BMD being identical.

GC has a prime role in the treatment of RA despite its negative effects on BMD. Osteoporotic fractures take place with higher BMD values in patients treated with GC in comparison to untreated patients. The scientists have found that there is a considerable decrease of TBS in the patients being treated with GC when compared to the reduction of BMD. The data that was presented, exhibited a significant decrease in BMD in early symptoms of RA both at the hip and spine after one tear from the onset of the disease. No significant reduction was observed in hip and spine BMD between low and high GC treated patients, whereas TBS values at the end of one year were extensively lower in patients receiving a high dose of GC.

The Result from their Findings:

Thus, the findings suggested that exposure to Glucocorticoid (GC) has a significant influence on bone microarchitecture mediated by the modulation of the OPG system. Additionally, the data depicts the potential of TBS involving the role of determining the early changes of bone quality. This bone score could give supplementary details regarding bone status in RA in addition to BMD. Further research is needed to determine the relationship between TBS changes and GC treatment, and the possible roles of other parameters that could affect TBS.

Also read: Reboxetine and Butyl-bromide: Drugs to solve sleep apnea issues

Reference:

  1. Corrado, A., Rotondo, C., Mele, A. et al. Influence of glucocorticoid treatment on trabecular bone score and bone remodeling regulators in early rheumatoid arthritis. Arthritis Res Ther 23, 180 (2021). https://doi.org/10.1186/s13075-021-02562-3

Author info:

Sayak Banerjee is a 3rd-year Biotechnology Engineering Student with a great interest in Immunology and Molecular genetics. He is a creative scientific writer in Bioxone with an inclination towards gaining knowledge regarding various sections of Biotechnology and emphasizing himself in various wet lab skills.

Publications:

  • https://bioxone.in/news/worldnews/car-t-cells-scientists-discover-on-off-switches-for-cell-immunotherapy/
  • https://bioxone.in/news/worldnews/neutrophil-derived-nanovesicles-a-novel-drug-delivery-system/
  • https://bioxone.in/news/worldnews/pig-to-human-heart-transplantation-a-solution-to-the-rarity-of-donor-organs/
  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP
  • AI Literacy in Early Childhood Education: Challenges and Opportunities

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged arthritis bone chronic disease disease fracture inflammation osteoporosis pathogenesis physiopathology rheumatoid arthritis rheumatology signaling

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • BiotechToday
  • World

Genetic pathway behind neurological disorder in Rett syndrome

BioTech Today July 9, 2021

Sneha Singhal, Jaypee Institute of information technology, Noida What is the Rett Syndrome? Rett syndrome also called RTT, is a rarely occurring genetic neurological or brain disorder. As a developmental disorder, it is found mostly in girls. There are severe functional impairments associated with Rett syndrome, affecting nearly every aspect of the child’s life. Language […]

Genetic pathway

Related Post

  • BiotechToday
  • World

A potential entry point in autophagosomes regulation

BioTech Today June 22, 2021June 21, 2021

Akash Singh, Banaras Hindu University Autophagy, often blamed for senescence, is a conserved process that promotes cellular homeostasis by degrading cytosolic components (sometimes referred to as cargo). This cargo sequestered into autophagosomes, which are double-membrane vesicles that are primarily carried in the retrograde direction to the perinuclear area, where they combine with lysosomes, ensuring cargo […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Genotype-Tissue Expression (GTEx) project reveals functional large-effect rare variants (RVs) now can be recognized across human tissues

bioxone September 17, 2020September 17, 2020

-Sristi Raj Rai, Amity University Kolkata In the whirlpool of diseases that strike humans, how worthy will it be to pinpoint the origin behind by just using 4 English alphabets that conclude specie’s fate? Hidden in 98% non-coding regions occurring in the large size of 6.4 bn bp human genome, with minor allele frequency (MAF) […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

A New way to Fight Diseases?

bioxone November 17, 2020November 17, 2020

Shrayana Ghosh, Amity University Kolkata Recently a mechanism has been determined by which microRNAs can be degraded by cells. This was discovered by researchers at UT Southwestern Medical Center. The information sheds light on the working of cells and how that can be used to establish a new way to combat infectious diseases and cancer. […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Exogenous Klotho as a Cognition Booster in Aging Primates

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy